ANIX NASDAQ
Credit Risk of going bust: lower than 83% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Anixa Biosciences, Inc. would be worth roughly what it owes.
Total debt $174K against a stock market value of $114.0M.
Distance to default 10.54 (Merton model): prices to 2026-10-27, balance sheet 2026-07-31, debt counted $87K (short-term plus half of long-term), stock volatility 66.5%; Altman Z'' -46.97. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Jose, CA 95118
US
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Titterton Lewis H jr | P-Purchase | 8,000 | $2.98 | 2026-10-23 |
| KUMAR AMIT | P-Purchase | 8,000 | $2.72 | 2026-10-22 |
| Catelani Michael | P-Purchase | 5,500 | $2.84 | 2026-09-30 |
| Baskies Arnold M | P-Purchase | 5,000 | $2.76 | 2026-09-24 |
| KUMAR AMIT | P-Purchase | 7,000 | $2.78 | 2026-09-24 |